PTC Therapeutics Stock Earns RS Rating Upgrade To 83

The Relative Strength (RS) Rating for PTC Therapeutics (PTCT) stock climbed into a new percentile Monday, with a rise from 80 to 83.

↑
X

NOW PLAYING
Stock Market Exposure: How To Make Incremental Portfolio Management Decisions

This unique rating tracks technical performance by showing how a stock’s price action over the last 52 weeks measures up against that of other stocks on the major indexes.

Decades of market research reveals that the market’s biggest winners often have an 80 or better RS Rating as they launch their biggest runs.

Looking For The Best Stocks To Buy And Watch? Start Here

Is PTC Therapeutics Stock A Buy?

PTC Therapeutics stock reclaimed its 50-day moving average and is working on a consolidation with a 40.69 entry. See if the biotech stock can break out in heavy trading.

The biotech company posted 0% EPS growth last quarter, while sales growth came in at -13%.

PTC Therapeutics stock holds the No. 152 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics (ADMA), SIGA Technologies (SIGA) and Catalyst Pharmaceuticals (CPRX) are among the top 5 highly rated stocks within the group.

YOU MAY ALSO LIKE:

MarketSurge’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks